# Successful Modeling and Simulation in a Consortium: A Recipe for Success

Brian Corrigan, PhD

Head, Clinical Pharmacology, Global Product Development

Pfizer, Groton, CT USA

November 6, 2017



# **Conflict of Interest and Acknowledgements**

- Brian Corrigan is an Employee of Pfizer
- Thanks to
  - Klaus Romero and Diane Stephenson (C-Path)
  - Jim Rogers and Marc Gastonguay (Metrum)
  - Kaori Ito and Haoyu Wang (Pfizer)
  - CAMD members



# Outline

- Why a Consortia Approach to MIDD and DDT Tools Makes Sense
- Leverage Past Consortia Success
  - Contrast CAMD /HD-RSC to demonstrate Consortia Approach to DDT
    - A Clear Plan
    - Data Standards
    - Clear Context of use
    - Pre specification of work
    - Prioritization
    - Regulatory Path(s) for acceptance
    - Tools (not models)



# Developing a DDT in A Consortium: Why?



# MIDD is used End-to-End in R&D



# The Data Tsunami



DATA >> resources to interrogate/understand it (bigger than individual organizations can make or maintain)







### Model for a disease platform and/or group of targets

Disease progression and patient characterization in Alzheimer, diabetes, rare disease. etc

Precompetitive development of Systems Pharmacology Models (eg immunogenicity)

### Model for a standard molecule

Itraconazole PBPK model

### Model/strategy for a clinical pharmacology area

**TQT Study Waivers** 

Pediatric Strategy

### Labeling for Special Population



#### Original Manuscript

Utility of Model Based Approaches for Informing Dosing Recommendations in Specific Populations: Report from the Public AAPS Workshop

Issue

ACO?

Clinical

Islam R. Younis PhD<sup>1,\*</sup>, J. Robert Powell PharmD<sup>2</sup>, Amin Rostami-Hodjegan PharmD, PhD<sup>3</sup>, Brian Corrigan PhD<sup>4</sup>, Norman Stockbridge MD, PhD<sup>5</sup>, Vikram Sinha PhD<sup>8</sup>, Ping Zhao PhD<sup>1</sup>, Pravin Jadhay PhD, MPH7, Bruno Flamion MD, PhD<sup>8</sup> and Jack Cook PhD<sup>4</sup>

DOI: 10.1002/jcph.787

This article is protected by copyright. All rights reserved

The Journal of Clinical Pharmacology Accepted Article (Accepted, Pharmacology unedited articles published online and citable. The final edited and typeset version of record will appear in future.)



# A Recipe for Success in a DDT Consortia



- 1 TEASPOON OF IDEAS
- 1/2 CUP OF GOODWILL
- 1 PINCH OF POSITIVITY
- 3/4 CUP OF IMAGINATION
- 1 LB OF LEADERSHIP
- 2 SPOONFULS OF TEAMWORK
- 3 TABLESPOONS OF CHALLENGE

Serve warm with a large helping of patience



- *1 Tonne* of good ideas
- 500 *mbq* of "radiant enthusiasm"
- XVI stone historical data
- 1/2 gallon (imp) of new biomarkers
- 0.487 L of sweat
- 47.8 g of good luck
- 1 New York second to complete

Defined as the time between a green light and a cab honking in NYC (aka the shortest unit of time in the multiverse)



# **Data Standards**



# Data Standards ACCELRATE CURES

	Accelerating the for Huntington'	ccelerating therapeutic development or Huntington's disease		
Preclinical Research	Scientific Publications	Community Resources 🔻	News & Video 🔻	About Us 🔻

### September 11, 2017

### C-Path, CHDI Foundation, and CDISC Announce Public Review Period for Huntington's Disease Therapeutic Area User Guide

TUCSON, AZ, NEW YORK, NY, and AUSTIN, TX – September 11, 2017 – Critical Path Institute (C-Path), CHDI Foundation, Inc. (CHDI), and The Clinical Data Interchange Standards Consortium (CDISC) announce the availability of a draft Huntington's disease (HD) Therapeutic Area User Guide (TAUG-HD v1.0) for public review. The TAUG-HD v1.0 describes how HD clinical data should be recorded in a standardized database to establish common best practices across the healthcare industry for the recording, reporting, and sharing of clinically relevant disease-specific metadata, research data, and patient information. Use of the standard will allow the HD research community to compare and contrast data from different studies more easily and with more scientific rigor, and will make it easier for researchers to understand natural history, biomarker, and trial data in the future. It will also facilitate regulatory submissions for novel therapeutics.



### 2. HD Modeling Working Group

This working group will be responsible for developing a quantitative clinical trial enrichment platform, based on a comprehensive disease progression model for manifest HD. This group will also lead subsequent modeling efforts, based on available data and specific needs in HD drug development. This effort will include the development of a clinical trial simulation tool, based on the expansion of the HD drug disease trial model with inclusion of a placebo effect model, a drug effects model, and a drop-out model for manifest stages of HD. Both, the quantitative clinical trial enrichment platform and the clinical trial simulation tool are intended to be submitted for regulatory acceptance.

### Goals:

- Develop and implement a modeling analysis plan for a comprehensive disease progression model, including proposed context-of-use, based on a survey of existing HD models. The initial focus will be a model-based clinical trial enrichment tool aimed to optimize the clinical trial design.
  - Coordinate and lead face-to-face meetings with regulators based on modeling submissions.
  - Consider pursuit with additional regulatory agencies.
- Develop and deliver on an HD-RSC publication strategy to communicate modeling and simulation achievements.

# Outlines the specific questions we want to answer and what data we need to answer them



# MODEL-BASED CLINICAL TRIAL ENRICHMENT PLATFORM: PROPOSED CONTEXT-OF-USE STATEMENT

**General Area:** A model-based clinical trial enrichment platform to help inform, through simulations, the definition of inclusion/exclusion criteria, enrichment strategies and stratification approaches for Phase II and Phase III studies evaluating therapeutic candidates for MCI.

**Target Population for Use:** Patients with aMCI. Clinical symptoms of aMCI are defined for this purpose as MMSE scores between 24-30 (inclusive), a memory complaint, objective memory loss measured by education adjusted scores on Wechsler Memory Scale Logical Memory II, a CDR of 0.5, absence of significant levels of impairment in other cognitive domains, essentially preserved activities of daily living, and an absence of dementia (ADNI criteria).

Stage of Drug Development for Use: Phase II and III clinical stages of MCI drug development.

**Intended Application:** Simulations based on this platform will allow development teams to inform the definition of subject selection, entry criteria, enrichment strategies and stratification approaches for Phase II and Phase III studies evaluating therapeutic candidates for MCI, by helping to define subpopulation progression rates in CDR-SB over the course of the trial.

Aligns Consortia, Workgroup, Collaborators, HAs around the Objective/Scope Defines Data Requirements and Potential analyses that may be required



# Socialize the Context of Use

- To All Stakeholders
  - Is it useful?
    - Does it answer your questions
- As early as possible
  - Avoids surprises/rework





The **specific aims** for the first phase of the HD-RSC are to establish:

- i) <u>Clinical Data Standards</u>: Finalize development of consensus clinical data standards (CDISC format) and ensure their dissemination to the HD research community.
- ii) <u>HD Trial/Study Database</u>: Create a secure online HD Database of integrated, CDISC-standardized patient-level clinical trial and observational study data, accessible to qualified researchers.
- <u>HD Progression Model</u>: Apply modeling and computational analysis strategies to the unified HD Database to develop a comprehensive quantitative model of disease progression at defined stages of HD.
- iv) <u>Quantitative Drug Development Tool</u>: Achieve formal regulatory acceptance of a Quantitative Drug Development Tool for Clinical Trial Enrichment, based on the HD progression model.
- v) <u>Quantitative Trial Model</u>: Develop a quantitative drug/disease trial model for manifest HD.
- vi) <u>Clinical Trial Simulation Tool</u>: Achieve formal regulatory acceptance of a Clinical Trial Simulation Tool, based on the trial model, to support efficient design of HD clinical trials.



## What is Disease Progression Modeling?



- the progression in time of a disease in an individual is represented as a mathematical function.
- Initially, a model is produced that characterizes a given disease's time profile in the absence of therapeutic intervention; this is a base model.
- Changes due to active treatment are superimposed onto the base model to simulate the effect on the disease of a drug.
- Disease progression models offer greater insight into data obtained from clinical trials, allowing for better study designs.



# **Disease Drug Progression Model in Clinical Trial**

$$S(t) = S_0 + \alpha \cdot t + f_{pbo}(t) + f_{drug}(t) + \varepsilon$$

S<sub>0</sub>: baseline disease "state" S(t): expected "state" at a time "t"  $\alpha$ : disease progression rate *t*: time  $\varepsilon$ : prediction variability  $f_{pbo}(t)$ : placebo effect  $f_{drug}(t)$ : symptomatic drug effects

ω ဖ ADAS-cog (change from baseline) underlving disease 4 progression 2 placebo response disease modifying 0 Ņ symptomatic drug response 4 0 6 12 26 52

Time (Week)

Note: if the drug is disease modifying (DM) type, the effect is on the slope ( $\alpha$ ):

$$S(t) = S_0 + \underline{\alpha \cdot f_{DM}(t)} \cdot t + f_{pbo}(t) + \varepsilon$$

.. or combination with symptomatic effect



Deterioration

# **DDT and Trial Simulations: Optimize Study Desgin**





# AD Drug-Disease-Trial Model Integrating the Clinical Trialist's World





# A Clear Pathway For Acceptance of Community DDTs

## C-Path/FDA pioneered the pathway for Regulatory acceptance of Model Based DDTs



#### SHORT REPORT

Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop

Klaus Romero · Vikram Sinha · Sandra Allerheiligen · Meindert Danhof · Jose Pinheiro · Naomi Kruhlak · Yaning Wang · Sue-Jane Wang · John-Michael Sauer · J. F. Marier · Brian Corrigan · James Rogers · H. J. Lambers Heerspink · Tawanda Gumbo · Peter Vis · Paul Watkins · Tina Morrison · William Gillespie · Mark Forrest Gordon · Diane Stephenson · Debra Hanna · Marc Pfister · Richard Lalonde · Thomas Colatsky

U.S. Food and Drug Administration Protecting and Promoting Your Health					Ale 2 Index   Pelow FDA   En DayAle Dearch FDA				
Hore Pool Dupp	Medical	Devices Reductor-Emitr	ng Products Véccines, I	Stood & Biologics Anim	al & Veterinary Cosmet	ics Tobacco Product			
Home > Drugs > Development	nt & Appro	val Process (Drugs)							
Development & Approval Presens (Drugs)		Drug Deve Initiative	elopment	Tools: Fit-	for-Purpos	80			
Drug Development Tool Progra and Initiatives		f anne 🖉 mear	in unitin @ Post 1	8 EIAL & PANT					
Guidance Documents for Drug Applications	9	Background							
Laws, Regulations, Policies a Procedures for Drug Applicati	and ions	The Fit-for-Purpose (Ff development program	FP) Initiative provides a s. Due to the evolving n	pathway for regulatory ature of these types of matics of 18 dece	acceptance of dynamic f drug development too	t tools for use in drug ds (DDTs) and the			
Letter of Support initiative		deemed FFP based or provided. The FFP det	n the acceptance of the emination is made red	proposed tool followin data available in an eff	g a thorough evaluation of to facilitate one electronic	n of the information dilication of these inc			
How Drugs are Developed and Approved	*	provides. The FFF version and in a made publicity analasies in an error to facilitate greater utilization of these too in drug development programs.							
Development Resources	*	Contact Us For more information about the PFP initiative, cleane contact DrucDevelopmentTools/NHA kite row							
Conducting Clinical Trials		Fit-For-Purpose Tools	and Supporting Inform	ations					
Conducting Clinical Trials Forms & Dubritssion Requirements	÷	Pit-For-Purpose Tools	and Supporting Inform	Test	Total Company of	Insuance Date and Supporting			
Conducting Clinical Trials Roma & Dubritssion Requirements Manufacturing	•	Disease Area	and Supporting Inform	Teel	Trial Component	Issuance Date and Supporting Information			
Conducting Clinical Trials forms & Submission Requirements Manufacturing CDER Small Business and nducty Assistance	•	Disease Area Alzheiner's disease	Bubmitter Submitter The Coalition Against Major Diseases (CAMD)	Teel Disease Model: Placebo Disease Progression	Trial Component Demographics, Drop- out	Issuance Date and Supporting Information Issued June 12, 201			
Conducting Clinical Trails forms & Dubribalion Repulsements Manufacturing CDER Small Business and Industry Assistance Drug Innovation	•	PisPor-Purpose Tools Disease Area Alzheimer's disease	and Supporting Inform Submitter The Coalition Against Major Diseases (CAMD)	Teel Disease Model: PlaceborDisease Progression	Trial Component Cemographics, Drop- Gut	Issuance Date and Supporting Information Issued June 12, 201 • Determination Letter The tool is feely evolution at			
Denducting Clinical Trads Forms 5 Dubritisation Regularisments CDER Development Social Industry Assistance Drug Innovation Drug Development Tools Dualification Programs	•	Pit-For-Purpose Tools Disease Area Atcheimer's disease	and Supporting Inform Submitter The Coalition Against Major Diseases (CAMD)	Teel Disease Model: Placebo Disease Progression	Trial Component Demographics, Drop- out	Insuance Date and Supporting Information Issued June 12, 201 • Determination Letter The tool is freely available at https://btimore. distance.programmer methoumgic/btimore.			
Cenducting Clinical Trats Proms & Subdimission Requirements Manufacturing CCER Small Exciness and Industry Assistance Chig Intervation Chig Development Trobs Cualification Programs Resources for You	* * * * * * *	Fill-For-Purpose Tools Disease Area Apheine/s disease Midtale	and Supporting Inform	Teel Disease Model: PlaceboilDisease Progression	Trial Component Demographics, Drop- out	Incurance Date and Supporting Information Inscend June 12, 201 • Determination Latin The tool is heavy exclude at disease-propersion di disease-p			
Conducting Clinical Trats Frems 8: Submission Regulaments CDER David Examples CDER David Examples CDER David Examples Comp Innovation Comp Development Tools Comp Development Tool Resources for You	•	Pit-For-Purpose Tools Disaise Area Atthemark Steale Multiple Multiple	And Supporting Inform	Teel Teel Disease Model PiccoboDisease Progression Statistical Method	Trial Component Demographics, Drop- out Dose-Finding	Insurance Date and Buggerting Information Insured June 12, 201 • Deterministion Littler The tool is heatly analative at the tool is heatly analative at the tool analative at the tool analative at the tool is heatly and the tool is not at the tool is not at tool is not at the tool is not at tool			
Conducting Clinical Yints Proms 5 Dubrinsion Programmers Manufacturing CCER Smull Sessions and Industry Assistance Drug Inneuration Chug Development Tools Programs and Initiatives	•	Fill-For-Purpose Tools Disease Area Apheine's disease Multiple	And Supporting Inform	Teel Disase Model Piccebo Disese Propession Distancel Method	Trial Component Demographics, Drog- out Dose-Priding	Iterations Date and Supporting Internations Instant June 12, 201 Between June 12, 201 Instant June 11, 201 Between June 12, 201 Between			
Conducting Cloked Trats Forms & Subdimission Requirements Menufacturing COER Small Business and Industry Assistance Drug Intervation Drug Development Tools Distification Programs Resources for You • Drug Development Tool Programs and Industries		Pit-Por-Purpose Tools Disease Area Atthemark disease Multiple	And Supporting Inform	Veel Disease Model: Placebol Disease Model: Placebol Disease Model: Placebol Disease State Propression Districted Method	Trial Composent Demographics, Drop- out Dose-Finding	Iterations Date and Supporting Indernation Interest June 12, 201 - Determination Lattice The tool is heady methods at Abarbane description of a state of the state of the state description of the state description of the state description of the state description of the			

http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm505485.htm





The total journey took 1317 days (3 years, 7 months and 9 days).

- On June 12, 2013 the FDA determined the CTS tool was "Fit for Purpose."
- On September 19, 2013 the EMA determined the CTS tool was "Qualified for Use."

		Submis	ssion for R	legulatory E	valuation			
NOVEMBER 3, 2009         DECEMBER 21, 2009           CAMD Coordinating Committee Meeting         FDA Letter of Intent	DECEMBER 23, 2009 Cover letter and Briefing Booklet to FDA	APRIL 22, 2010 FDA Written feedback	APRIL 28, 2010 Meeting with CDER Alzheimer's Disease Modeling Review Team	NOVEMBER 22, 2011 Submission to FDA	MARCH 27, 2012 Comments received from FDA	AUGUST 22, 2012 Responses to FDA submitted	JANUARY 7, 2013 Detailed discussion with FDA regarding the programming code	JUNE 12, 2013 AD trial simulation tool deemed fit for purpose as a drug development tool
EUROPEAN MEDICINES AGENCY	Letter of Intent to EMA FEBRUARY 10, 2010	Briefing package to EMA JUNE, 2010	Written response from EMA AUGUST 23, 2010	SA meeting with EMA SEPTEMBER 1, 2010	Submission to EMA MARCH 20, 2013	SAWP meeting with CAMD JUNE 4, 2013	Face-to-face meeting with SAWP JUNE 7, 2013	AD trial simulation tool qualified for use in trial design JUNE 27, 2013



### **OBJECTIVES**

An open-source web-based Alzheimer's Disease (AD) trial simulation application was developed using the R packages "shiny" and "adsim". The app allows for simulation, visualization and reporting of simulation results of common AD trial designs utilizing ADAScog, a common measure of cognition used as a primary endpoint in AD clinical trials. The tool is designed for all users in a clinical development team, including individuals without knowledge in R.

### RESOURCES

Hosted Application: https://isop.shinyapps.io/Alzhei mer/. Source Code: https://github.com/why94nb/s hiny-app-for-adsim/.

> Haoyu Wang<sup>1</sup>,Dan Polhamus<sup>2</sup>, Jim Rogers<sup>2</sup>, Klaus Romero<sup>3</sup>, Puneet Gaitonde<sup>4</sup>, Brian Corrigan<sup>4</sup> and Kaori Ito<sup>4</sup>

<sup>1</sup>Department of Statistics, North Carolina State University, Raleigh, NC; <sup>2</sup>Metrum Research, Tarrifville, CT; <sup>3</sup>Critical Path Institute , Tucson, AZ; <sup>4</sup>Pfizer Inc., Groton, CT

#### METHODS

Individual and summary level data from AD patients was used to develop a longitudinal disease Progression model,

which was then developed as an R Package (adsim) for trial simulation in mild and moderate AD. Using adsim and shiny, an open-source R based application suitable for use by members of a drug development team was developed. The code is maintained in an open source repository to allow for ongoing use/upgrade by anyone.

Patient Table Both baseline information table and longitudinal bie for test case are available to download. Users can also download the full table (data for all the

1.00

Report

User can download

the information

About Sessior

Simulation in Alzheimer's Disease

**Interactive Web Application for Clinical** 

Trial Simulation and Reporting: R Shiny

with 'adsim' Package for Model-based

Simulation Set

Patient-leve

Spaghetti

Basline Information (Age, Gender, ApoE and MMSE) The app consists of six tabs that allow the user to set up, run, and view results from the simulation. The "About" tab contains information about the "adsim" package and a user guide for the app. Users can choose various trial design and drug effects in the "Simulation Set Up" tab. Spaghetti plots and figures about baseline information (gender, age, ApoE and MMSE) are available in the

A size com

Simulation Test

Summary

"Illustrative Statistics (Test)" tab and can be downloaded. A test statistics summary is shown in the "Simulation Summary" tab. In addition, patient tables(Both baseline information and longitudinal table) are downloadable for further analysis and the user can also download. A short report summarizing parameter settings and all the outputs generated during the simulation is also available.

### CONCLUSION

We have developed an opensource R shiny app to allow development team members to perform Alzheimer's Disease clinical trial simulation, utilizing an reproducible way to visualize simulation results and to share the results within the clinical team (clinical pharmacology, statistics and clinicians).

Journal of Pharmacokinetics Pharmacodynamics (ACOP W-27, 2016

# We Have Great Ingredients.....

- Skilled and Knowledgeable team
  - Both in HD and in Consortia
- Previous Consortia Experience
- Rich Data Sources
  - Understanding of importance of Data standards
- Clear understanding of the Disease
  - Emerging CGT approaches to therapy
- Innovative analysis techniques/tools available
- Clear Regulatory Path
- Patients waiting for us





